Protein Analysis using Mass Spectrometry: Accelerating Protein Biotherapeutics from Lab to Patient (Wiley Series on Pharmaceutical Science and Biotechnology: Practices, Applications and Methods)

Presents Practical Applications of Mass Spectrometry for Protein Analysis and Covers Their Impact on Accelerating Drug Discovery and Development

• Covers both qualitative and quantitative aspects of Mass Spectrometry protein analysis in drug discovery
• Principles, Instrumentation, Technologies topics include MS of peptides, proteins, and ADCs , instrumentation in protein analysis, nanospray technology in MS protein analysis, and automation in MS protein analysis
• Details emerging areas from drug monitoring to patient care such as Identification and validation of biomarkers for cancer, targeted MS approaches for biomarker validation, biomarker discovery, and regulatory perspectives
• Brings together the most current advances in the mass spectrometry technology and related method in protein analysis

Dr. Mike S. Lee is a biotechnology entrepreneur and Founder and President of Milestone Development Services. He actively participates in the development of new technologies and their integration into industrial settings.  Dr. Lee is a founder of the Annual Symposium on Clinical and Pharmaceutical Solutions through Analysis (CPSA). These unique events, held in the US, China and Brazil, highlight industry-related applications and feature sessions promoting discussion on real-world experiences with the latest analytical technology and industry initiatives. Dr. Lee is the author or co-author of over 50 scientific papers and patents. He received his BS degree in Chemistry at the University of Maryland in 1982. In 1985 and 1987, he completed his MS and PhD, respectively, in Analytical Chemistry from the University of Florida under the direction of Professor Richard A. Yost.

Dr. Qin C. Ji is a Research Fellow in the Department of Bioanalytical Sciences at Bristol-Myers Squibb, Princeton, New Jersey. His current job responsibilities include regulated bioanalytical support (with LC-MS/MS and ligand binding assays) for the development of biologic, new modality, and small molecule drugs in preclinical and clinical stages. He has authored and co-authored more than 60 peer reviewed articles and book chapters.  Prior to his current position, he held scientific and management positions at Abbott and Covance. Dr. Ji obtained his Ph.D. from Michigan State University and has completed Postdoctoral training at Mayo Clinic. He was awarded two President Awards and was an Associate Research Fellow in the prestigious Volwiler scientific society at Abbott Laboratories. He was also awarded a Chemistry Leadership Award at Bristol-Myers Squibb.